Showing 6,261 - 6,280 results of 18,079 for search 'significantly ((((((we decrease) OR (a decrease))) OR (nn decrease))) OR (larger decrease))', query time: 0.68s Refine Results
  1. 6261
  2. 6262
  3. 6263
  4. 6264

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  5. 6265

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  6. 6266

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  7. 6267

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  8. 6268

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  9. 6269
  10. 6270
  11. 6271
  12. 6272
  13. 6273
  14. 6274
  15. 6275
  16. 6276
  17. 6277
  18. 6278

    Supplementary Material for: The effectiveness of regionalization of perinatal care and specific facility-based interventions: A systematic review by Ali A.A. (19754238)

    Published 2024
    “…Results: Implementation of regionalization programs significantly decreased maternal and perinatal mortality. …”
  19. 6279

    VB2 cell fate analysis of <i>hlh-17</i>, <i>hlh-31</i>, and <i>hlh-32</i> mutant animals. by G. Robert Aguilar (13889674)

    Published 2025
    “…<p>(<b>A</b>) In <i>hlh-17/31/32</i><sup>null</sup> mutants, VB2 adopts a VB1-like NeuroPAL <i>(otIs669)</i> coloring. …”
  20. 6280

    Data Sheet 1_A comparative analysis of cluster based interventions on healthcare-associated infections in a tertiary care hospital in China.doc by Ya Zou (6527423)

    Published 2025
    “…Additionally, a notable decrease in NSIs per 10,000 patient days was observed during the same comparison period, with a statistically significant difference (12.17 ± 1.47 vs. 9.20 ± 1.07, p = 0.006).…”